Personalised Medicine and Patient Safety

Symposium programme

The era of personalised medicine represents a paradigm shift in healthcare: by tailoring diagnostics and therapies to each patient’s unique genetic profile, lifestyle and environment, clinicians can achieve far better outcomes than with one-size-fits-all approaches. In practice, this means more accurate diagnoses and more effective, individualized treatments – and crucially, a
substantial reduction in harmful side effects. For example, by understanding a patient’s genetic makeup, providers can predict and avoid adverse drug reactions, directly enhancing patient safety. Personalised medicine thus holds great promise for safer, more effective patient care, making it a pivotal focus of current research.

08:30

Registration
08:50 - 09:00

Opening of the symposium 
09:00 - 09:45

Bridging pharmacogenomics, in vitro models and AI for next-generation personalization of drug treatment

Magnus Ingelman-Sundberg, Senior Professor, BSc.Med, PhD, Department of Physiology and Pharmacology, Section of Pharmacokinetics, Karolinska Institutet, Stockholm
09:45 - 10:30

PGx and drug transporters
Mikko Niemi, Professor, MD, PhD, Dept. of Clinical Pharmacology, University of Helsinki
10:30 - 11:00

Coffee break and networking
11:00 - 11:30

Renal biomarkers
Morten Baltzer Houlind PhD, PostDoc, Department of Clinical Research, Hvidovre Hospital and Dept. of Drug Design and Pharmacology, University of Copenhagen
11:30 - 12:00

Can PGx testing contribute to prevention of medication-related admissions to the emergency department
Louise W.S Christensen, MSc. PhD student, Department of Clinical Research, Hvidovre Hospital and Dept. of Drug Design and Pharmacology, University of Copenhagen
12:00 - 12:30

PGx in Psychiatry

Marlene Bentestuen, MD, PhD student, Psychosis Research Unit, Aarhus University Hospital Psychiatry & Dept. of Clinical Medicine, Aarhus University
12:30 - 13:15

Lunch and networking
13:15 - 14:00

Who are we really treating? Host genome profiling – and treatment effects
Kjeld Schmiegelow, Professor, MD, DMSc, Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet
14:00 - 14:30

Personalised treatment with Imatinib in patients with leukemia
Anna Buhl Rasmussen, MD, PhD student,  Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet
14:30 - 15:00

Coffee break and networking
15:00 - 15:30

Imaging biomarkers of Vascular Dysfunction – Can we optimize Diagnosis and target treatment of peripheral neuropathy?
Trine Andresen, Associate Professor, MSc(pharm), PhD, Department of Health Science and Technology, Translational Pain Neuroscience and Precision Health, Center for Neuroplasticity and Pain, Aalborg University
15:30 - 16:15

Clinical implementation of DPYD testing

Stig Ejdrup Andersen, Associate Professor, MD, PhD, Department of Clinical Pharmacology, Zealand University Hospital
16:15 - 16:30

Closing remarks
16:30 - 17:30

Farewell networking between senior researchers/clinicians and PhD students fuelled by snacks & drinks

The symposium is organized on behalf of the graduate programme in pharmaceutical sciences, Drug Research Academy, and the Danish Society for Personalised Medicine by Morten Baltzer Houlind, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen.

The symposium is free of charge and open for attendance by all interested parties. In order to avoid food waste it is necessary to register by 11 November to: llc@sund.ku.dk

It will also be possible to participate via ZOOM. If you wish to participate via ZOOM, please send an email marked "online participation" to llc@sund.ku.dk, no later than 20 November and you will receive a link to participate.